Antibody Contract Manufacturing Market Research: Growth Projections and Trends 2030
Uncover key drivers, emerging technologies, and competitive movements shaping the antibody contract manufacturing market from 2026–2035 with trusted insights from The Business Research Company
Across 2026–2030, what is the expected market valuation path of the Antibody Contract Manufacturing Market?
The antibody contract manufacturing market has experienced rapid expansion in recent years. It is anticipated to grow from $16.79 billion in 2025 to $19.32 billion in 2026, at a compound annual growth rate (CAGR) of 15.0%. This historical growth can be attributed to an increase in biologics development pipelines, greater outsourcing by biopharmaceutical companies, the broadening of mammalian cell culture platforms, rising clinical trial activity involving antibodies, and the availability of specialized CMO infrastructure.
The antibody contract manufacturing market is projected to experience substantial expansion over the coming years. By 2030, its size is anticipated to reach $34.72 billion, exhibiting a compound annual growth rate (CAGR) of 15.8%. This anticipated growth during the forecast period is driven by several factors, including the escalating demand for commercial-scale antibody production, increased funding for next-generation biologics, a heightened emphasis on economical manufacturing approaches, the expansion of personalized medicine development pipelines, and more frequent regulatory approvals for antibody-based treatments. Key trends characterizing this period encompass the enlargement of large-scale antibody manufacturing capabilities, a growing acceptance of single-use bioprocessing technologies, an increasing need for bispecific antibodies and ADCs, a greater emphasis on adaptable and scalable production frameworks, and a stronger commitment to regulatory adherence and quality assurance.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12665&type=smp
Which Drivers Are Supporting The Rise Of The Antibody Contract Manufacturing Market?
The anticipated increase in clinical trials is poised to boost the antibody contract manufacturing market moving forward. These research studies involve human participants to assess the safety and efficacy of new medical treatments, interventions, or diagnostic procedures. As the volume of clinical trials utilizing antibody-based therapeutics or diagnostics grows, there is an escalating demand for high-quality antibodies, requiring a timely and compliant supply for these trials. For example, data from ClinicalTrials.gov, a component of the National Institutes of Health (NIH), a US-based government agency dedicated to medical research, indicated that registered clinical trial studies across all 50 states of the United States and 221 countries rose from 399,499 in 2022 to 437,533 in 2023, as of May 2023. Moreover, about 241,498 studies, or 53% of the total, were registered outside the United States, contrasting with 140,492 studies (31%) registered exclusively within the United States. Hence, the growing number of clinical trials serves as a key driver for the expansion of the antibody contract manufacturing market.
What Leading Segments Are Studied In The Antibody Contract Manufacturing Market?
The antibody contract manufacturing market covered in this report is segmented –
1) By Product: Monoclonal Antibodies, Polyclonal Antibodies, Other Products
2) By Source: Mammalian, Microbial
3) By Scale Of Operation: Preclinical, Clinical, Commercial
4) By End-User: Biopharmaceutical Companies, Research Laboratories, Other End Users
Subsegments:
1) By Monoclonal Antibodies: Therapeutic Monoclonal Antibodies, Diagnostic Monoclonal Antibodies
2) By Polyclonal Antibodies: Research Polyclonal Antibodies, Therapeutic Polyclonal Antibodies
3) By Other Products: Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Fusion Proteins
Which Trends Are Guiding The Evolution Of The Antibody Contract Manufacturing Market?
Major companies engaged in the antibody contract manufacturing market are concentrating on developing innovations, such as single-use technology, which minimizes the risks of cross-contamination and reduces operational expenses. Single-use technology (SUT) refers to disposable components and systems employed in biopharmaceutical manufacturing processes. For instance, in September 2024, Merck & Co., a US-based pharmaceutical company, unveiled the Mobius ADC Reactor, designed to enhance the production of antibody-drug conjugates. This new single-use reactor, specifically created for antibody drug conjugate manufacturing, significantly improves production efficiency by 70% compared to traditional stainless steel or glass methods. Its disposable design reduces cross-contamination risks and operational costs, leading to quicker turnaround times. Additionally, advanced film technology enhances bag strength and leak resistance, ensuring the integrity of highly potent active pharmaceutical ingredients. This innovation assists biopharmaceutical companies in producing crucial therapies more safely and efficiently.
Which Leading Companies Dominate The Antibody Contract Manufacturing Market Share?
Major companies operating in the antibody contract manufacturing market are Lonza Group AG, Catalent Inc, Samsung Biologics Co Ltd, Wuxi Biologics Cayman Inc, Thermo Fisher Scientific Inc, Boehringer Ingelheim BioXcellence, AGC Biologics, FUJIFILM Diosynth Biotechnologies, AbbVie Inc, Charles River Laboratories International Inc, mAbxience, KBI Biopharma Inc, Abzena Ltd, Just-Evotec Biologics, Northway Biotech, Cerbios-Pharma, Scorpius BioManufacturing, Lotte Biologics, Rentschler Biopharma SE, Cytiva (Life Sciences CDMO), Xcellon Biologics, Celonic AG, Syngene International Ltd
Access The Complete Report For Deeper Market Insights:
How Does The Antibody Contract Manufacturing Market Perform Across Major Global Regions?
North America was the largest region in the antibody contract manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibody contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Antibody Contract Manufacturing Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=12665&type=smp
Browse Through More Reports Similar to the Global Antibody Contract Manufacturing Market 2026, By The Business Research Company
Antibody Discovery Market Report 2026
https://www.thebusinessresearchcompany.com/report/antibody-discovery-global-market-report
Vaccine Contract Manufacturing Market Report 2026
Biopharmaceuticals Contract Manufacturing Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
